No Data
No Data
No Data
No Data
No Data
Citibank: Maintaining the China People's Insurance Group's “Buy” Rating and Lowering the Target Price to HK$3.4
Citigroup released a research report stating that the China People's Insurance Group (01339) earnings forecasts per share for 2024 and 2025 were lowered by 3.6% and 3.7%, respectively, to reflect last year's performance, and the target price of People's Insurance was lowered from HK$3.6 to HK$3.4, maintaining a “buy” rating.
新浪港股Apr 5 00:01 ET
China People's Insurance Group: People's Insurance's original insurance premium income of 62,828 billion yuan in January increased 2.7% year-on-year
China People's Insurance Group (01339) announced that from January 1, 2024 to January 31, 2024, the original insurance premium income obtained by the company's subsidiaries China Property Insurance Co., Ltd. (China Life Insurance), and China People's Health Insurance Co., Ltd. (Human Health Insurance) was RMB 62,828 billion, RMB 32.04 billion and RMB 11.198 billion, respectively, up 2.7% year on year, down 18.5% year on year and 4.5% year on year .
新浪港股Feb 21 04:05 ET
China People's Insurance Group (01339.HK)'s original premium income in 2023 reached 661,649 billion yuan, up 6.86% year-on-year
Gelonghui, January 12, 丨 China People's Insurance Group (01339.HK) announced that the company's original insurance premium income from January 1, 2023 to December 31, 2023 through the company's subsidiaries Human Insurance, Life Insurance and Human Health was RMB 515.807 billion, RMB 10.634 billion and RMB 45.208 billion respectively, totaling RMB 661,649 billion, an increase of 6.86% over the previous year.
Gelonghui FinanceJan 12 03:37 ET
China Financial Insurance and Human Insurance Reinsurance sign reinsurance framework agreement
China Financial Insurance (02328) announced that on December 29, 2023, the company signed a reinsurance framework agreement with Human Insurance Reinsurance. According to this agreement, the company agreed to distribute premiums and collect processing fees from Human Insurance Reinsurance, and Human Insurance Reinsurance agreed to distribute premiums and collect processing fees from the company. As a property insurance company, the company reinsures part of the covered risk to reduce risk. Human Insurance Reinsurance was jointly initiated by the China People's Insurance Group and the company. It is the fourth Chinese-owned corporate reinsurance company established in China. The company entered into this agreement with Human Insurance Reinsurance to achieve risk diversification and stability
新浪港股Dec 29, 2023 04:57 ET
China Resources Pharmaceuticals: China Resources Pharmaceutical Commercial Plans to Increase Registered Capital and Introduce External Investors
China Resources Pharmaceutical (03320) issued an announcement. The bidding process for the proposed subscription items expired on December 25, 2023, and China Resources Pharmaceutical entered into a subscription agreement with Beijing Pharmaceuticals, China Resources Pharmaceutical Investment and Investor Subscribers on December 28, 2023. According to this, China Resources Pharmaceutical Commercial has agreed to increase its registered capital from RMB 15 billion to RMB 4,646.5 billion to RMB 19.646.5 billion, of which the investor subscribers have agreed to subscribe for the total registered capital of RMB 3.04 billion, with a total cost of RMB 5.26 billion Yuan, and Beijing Pharmaceutical and China Resources
新浪港股Dec 28, 2023 19:55 ET
Haitong International: Maintaining China's financial insurance “superior to the market” rating, with a target price of HK$10.98
According to a research report released by Haitong International, China Financial Insurance (02328) maintains the “superior market” rating, with a target price of HK$10.98. The quality of the auto insurance business for human insurance is relatively good. In the auto insurance business, the share of private cars with low payout rates is relatively high, and channel rates are manageable. Therefore, the bank believes that the company's profit margin far exceeds that of small and medium-sized insurers, and that its competitive advantage will become more prominent in the second half of the comprehensive auto insurance reform. In 2022, the company's dividend ratio remained stable at 40%, and the dividend rate was 7.1%. The company announced results for the third quarter of 2023:1) Achieved net profit of 19.4 billion yuan in the first three quarters, -26.2% year-on-year; Q3 quarterly net profit of 150 million yuan
新浪港股Dec 19, 2023 21:04 ET
No Data
No Data